ESTRO 2025 - Abstract Book

S842

Clinical - Gynaecology

ESTRO 2025

Conclusion: This study showed that older patients desired more survival benefit from chemotherapy before opting for this treatment. Clinicians should be aware of the discrepancy between the median desired survival benefit in patients above 60 years and the actual 5% survival benefit chemotherapy provides. Especially among patients aged ≥70 years, there is heterogeneity in desired benefit of chemotherapy and in the importance rating of treatment duration and side effects, highlighting the need of recognizing individual differences and the imperative of shared decision making. References: 1. Post CCB, Mens JWM, Haverkort MAD, Koppe F, Jürgenliemk-Schulz IM, Snyers A, et al. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making. Gynecol Oncol. 2021;161(3):727-33. DOI: 10.1016/j.ygyno.2021.03.004. 2. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(8):1114-26. DOI: 10.1016/s1470 2045(16)30120-6. Keywords: Patient preferences, treatment benefit, age groups